ArticlePloS one2025
Epidemiological trends and projections to 2035 of hepatitis B burden in China, 1990-2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Using a crowdsourcing open call to generate hepatitis B and C stigma-reduction materials with medical students in China.BMC public health · 2026Article
- The global epidemiology of hepatocellular carcinoma.Hepatology communications · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) remains a major cause of liver disease and premature death globally, with China bearing a significant share of the burden. However, long-term trends and future projections of HBV burden in China remain insufficiently described, despite widespread infant vaccination and expanded antiviral therapy.
methodsWe analyzed hepatitis B-related mortality, age-standardized mortality rate (ASMR), disability-adjusted life years (DALYs), and age-standardized DALY rate (ASDR) in China from 1990 to 2021 using data extracted from the GBD 2021 database. Temporal trends were quantified by estimated annual percentage change (EAPC).
resultsBetween 1990 and 2021, the number of deaths from hepatitis B-related liver diseases in China increased from 215 thousand to 219 thousand (+1.83%), whereas the ASMR decreased from 23.86 per 100,000 to 10.68 (EAPC: -2.78). The disability-adjusted life years (DALYs) decreased from 7.78 million in 1990 to 6.61 million in 2021 (-15.04%), with the ASDR decreasing from 774 per 100,000-329 (EAPC: -3). Despite significant reductions in HBV mortality and DALYs, the growing burden of HBV-related liver cancer, particularly among older males, remains a critical concern. Targeted early screening and treatment strategies are urgently needed. Projections for 2035 indicate a continued decline in the overall burden of hepatitis B, with the liver cancer burden showing a fluctuating decrease.
conclusionDespite progress in HBV prevention and control, the increasing burden of hepatitis B-related liver cancer remains a major public health challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.